200um 638nm 2W Red Fiber Coupled Laser Module

The 200μm 638nm 2W Red Fiber Coupled Laser Module—a PDT-dedicated medical-grade optical light source optimized for clinical photodynamic therapy of tumors and pathological lesions. Tailored to the core requirements of PDT (photosensitizer absorption matching, controllable deep tissue energy delivery, clinical-grade power stability, and minimally invasive operation compatibility), this module leverages 638nm red light’s ideal biological tissue penetration characteristics, 200μm medical-grade fiber’s uniform energy distribution, and 2W stable CW output. It features full medical device compliance, compact structural design, and multi-dimensional safety protection, realizing precise, efficient, and safe laser energy transmission for PDT equipment—an ideal core light source for minimally invasive therapy of skin, digestive tract, respiratory tract, and gynecological superficial/deep lesions.

Core PDT-Dedicated Medical-Grade Advantages

1. 638nm Red Light: Optimal Wavelength for Clinical PDT Photosensitizer Activation

• 638nm (±5nm tolerance) high-purity red light is the golden wavelength for clinical PDT: perfectly matches the absorption peak of mainstream clinical photosensitizers (e.g., HpD, 5-ALA, Photofrin, Verteporfin), achieving ≥85% photosensitizer activation efficiency and generating a large amount of reactive oxygen species (ROS) to specifically kill pathological cells (tumor/lesion cells) without damaging normal tissue.

• Superior biological tissue penetration depth: deeper than 520/532nm green light and 405nm violet light, breaking through the limitation of shallow lesion therapy of short-wavelength lasers, and suitable for PDT of deep superficial lesions (e.g., esophageal cancer, bronchial cancer, cervical intraepithelial neoplasia) that cannot be treated by short-wavelength lasers.

• Narrow spectral linewidth (≤4nm FWHM) eliminates chromatic aberration of PDT equipment’s optical lens/probe system, ensuring uniform laser energy distribution at the fiber output end and avoiding local over-irradiation-induced normal tissue burns—critical for clinical PDT safety.

• Low autofluorescence interference with biological tissue: 638nm red light has no spectral overlap with the autofluorescence of human tissues/blood, avoiding interference with PDT real-time monitoring and ensuring accurate judgment of therapy endpoints by clinicians.

2. 200μm Medical-Grade Fiber Coupling: Balanced Energy Density & Minimally Invasive Delivery

• Equipped with medical-grade UV-resistant low-OH multimode silica fiber (200μm core, NA=0.22): the 200μm core diameter achieves a perfect balance of energy density and irradiation area, suitable for both small focal lesions (e.g., skin nevi, oral ulcers) and large-area superficial lesions (e.g., skin basal cell carcinoma, bladder cancer), avoiding insufficient therapy caused by too small a core diameter or normal tissue damage by too high energy density.

• Upgraded PDT-dedicated space coupling system with dual aspheric medical-grade glass lenses, achieving coupling efficiency ≥85%—minimizing optical loss and ensuring maximum effective power transmission to the lesion site. The fiber coupling end is sealed with medical-grade biocompatible adhesive, meeting the airtightness and cleanliness requirements of hospital clean rooms.

• Standard medical-grade SMA-905 fiber connectors: anti-pull, anti-bending, and compatible with mainstream clinical sterilization methods (ethylene oxide EO/ultrasonic/low-temperature plasma sterilization), adapting to the repeated sterilization and frequent minimally invasive operation needs of PDT equipment (endoscope/catheter/probe matching).

3. 2W Clinical-Grade Stable CW Output: Adaptive to Diverse PDT Lesion Therapy Demands

• 2W medical-grade stable CW output is the optimal power for clinical medium-power PDT: covers the full power demand of most clinical PDT scenarios—low power (0.3–1W) for small/ superficial lesions (e.g., skin freckles, oral cancer in situ), high power (1–2W) for large/deep superficial lesions (e.g., esophageal cancer, cervical cancer).